Eli Lilly Posts 79.3% Response Rate for Ovarian Cancer Drug
Photo: TokenPost
Eli Lilly and Company's investigational drug sofetabart mipitecan, known as Sofe-M, produced a 79.3% confirmed response rate with bevacizumab in Phase 1 testing of platinum-sensitive ovarian cancer, ahead of its Phase 3 program. The response measure applied to 29 women with measurable disease, 23 of whom responded. Six had complete responses and 17 had partial responses. The full group included 33 women, who had received a median of three prior systemic treatment regimens, ranging from one to six. Prior PARP-inhibitor use was listed for 67% of participants, while 70% had previously received bevacizumab. The data cutoff was July 6, 2026.
Source: TokenPost
